Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific highlights promising report on portfolio company Vortex BioSciences' cancer technology

The AIM listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology
Cancer cells
The technology was used to capture circulating tumour cells, in combination with the use of a novel immunofluorescence assay

NetScientific PLC (LON:NSCI) has noted that its portfolio company, Vortex BioSciences Inc, has announced a promising report published by Nature Scientific Reports.

The AIM-listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology.

READ: NetScientific hails progress of its portfolio companies in 2017

It added that the technology was used to capture circulating tumour cells (CTCs), in combination with the use of a novel immunofluorescence assay, for measuring programmed cell death ligand 1 (PD-L1) expression on the surface of the CTCs from patients with metastatic non-small cell lung cancer (NSCLC).

Commenting on the news, Francois Martelet, CEO of NetScientific and chairman of Vortex BioSciences said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients.

"Recent clinical trials of PD-1 and PD-L1 inhibitors have returned promising clinical responses, providing a rationale for use of the VTX 1 system in personalised medicine."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use